{"id":"W2091567174","doi":"10.1586/14737140.2015.1014343","title":"Dabrafenib in the treatment of metastatic or unresectable melanoma","year":2015,"lang":"en","type":"review","venue":"Expert Review of Anticancer Therapy","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Dabrafenib; Medicine; Trametinib; Melanoma; Metastatic melanoma; Oncology; Vemurafenib; Internal medicine; Clinical trial; Immunotherapy; Progression-free survival; Overall survival; Cancer research; Cancer; MAPK/ERK pathway; Kinase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005387164,0.0003977487,0.002063838,0.00006254272,0.00001900777,0.000007026594,0.0005301356,0.000118764,0.0001795953],"category_scores_gemma":[0.00004281489,0.0001830024,0.0005578274,0.0002887609,0.0001016682,0.000003288486,0.00002619054,0.00006830318,0.000005762713],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003093876,"about_ca_system_score_gemma":0.0007991566,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009327947,"about_ca_topic_score_gemma":0.00002403504,"domain_scores_codex":[0.9977643,0.0005343254,0.0008229971,0.0003640596,0.0002747259,0.0002395593],"domain_scores_gemma":[0.9983995,0.00007888726,0.0004687414,0.0009103015,0.00009089591,0.00005165158],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00007066696,0.0004675946,0.000002840196,0.01486259,0.0003220741,0.0000134997,0.0001533018,3.442335e-8,0.0001761841,0.00004691378,0.006662257,0.977222],"study_design_scores_gemma":[0.0005759004,0.00199281,6.978555e-7,0.013159,0.0001468645,0.00003336884,0.00003921276,2.147875e-7,0.0007841543,0.000007209969,0.9830636,0.0001969893],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00003983042,0.9969701,0.00001520333,0.00004754094,0.0001570121,0.001623101,0.0000709435,0.000002864791,0.001073462],"genre_scores_gemma":[0.00001797735,0.9981578,0.0003552857,0.0002682024,0.0002210727,0.0004831854,0.0002192283,0.00003842803,0.0002388497],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.977025,"threshold_uncertainty_score":0.7462622,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1136130243722451,"score_gpt":0.4255522667774826,"score_spread":0.3119392424052375,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}